Familial amyloid polyneuropathy

	WikiDoc Resources for Familial amyloid polyneuropathy
Articles
Most recent articles on Familial amyloid polyneuropathy Most cited articles on Familial amyloid polyneuropathy Review articles on Familial amyloid polyneuropathy Articles on Familial amyloid polyneuropathy in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Familial amyloid polyneuropathy Images of Familial amyloid polyneuropathy Photos of Familial amyloid polyneuropathy Podcasts & MP3s on Familial amyloid polyneuropathy Videos on Familial amyloid polyneuropathy
Evidence Based Medicine
Cochrane Collaboration on Familial amyloid polyneuropathy Bandolier on Familial amyloid polyneuropathy TRIP on Familial amyloid polyneuropathy
Clinical Trials
Ongoing Trials on Familial amyloid polyneuropathy at Clinical Trials.gov Trial results on Familial amyloid polyneuropathy Clinical Trials on Familial amyloid polyneuropathy at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Familial amyloid polyneuropathy NICE Guidance on Familial amyloid polyneuropathy NHS PRODIGY Guidance FDA on Familial amyloid polyneuropathy CDC on Familial amyloid polyneuropathy
Books
Books on Familial amyloid polyneuropathy
News
Familial amyloid polyneuropathy in the news Be alerted to news on Familial amyloid polyneuropathy News trends on Familial amyloid polyneuropathy
Commentary
Blogs on Familial amyloid polyneuropathy
Definitions
Definitions of Familial amyloid polyneuropathy
Patient Resources / Community
Patient resources on Familial amyloid polyneuropathy Discussion groups on Familial amyloid polyneuropathy Patient Handouts on Familial amyloid polyneuropathy Directions to Hospitals Treating Familial amyloid polyneuropathy Risk calculators and risk factors for Familial amyloid polyneuropathy
Healthcare Provider Resources
Symptoms of Familial amyloid polyneuropathy Causes & Risk Factors for Familial amyloid polyneuropathy Diagnostic studies for Familial amyloid polyneuropathy Treatment of Familial amyloid polyneuropathy
Continuing Medical Education (CME)
CME Programs on Familial amyloid polyneuropathy
International
Familial amyloid polyneuropathy en Espanol Familial amyloid polyneuropathy en Francais
Business
Familial amyloid polyneuropathy in the Marketplace Patents on Familial amyloid polyneuropathy
Experimental / Informatics
List of terms related to Familial amyloid polyneuropathy

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Familial amyloid polyneuropathy (FAP) or Corino de Andrade's disease, a form of Paramyloidosis, is a neurodegenerative autosomal dominant genetically transmitted disease, first identified and described by Portuguese neurologist Mário Corino da Costa Andrade, in the 50s. It is a fatal and incurable disease.

Cause

Familial amyloid polyneuropathy is inherited in an autosomal dominant pattern.

Being an autosomal dominant genetically transmitted disease, FAP is transmitted from parents to sons, one mutated gene being enough (in only one of the alleles), in any of the progenitors, for the disease to be passed on.

Pathology

FAP is characterized by the systemic deposition of amyloidogenic variants of the transthyretin protein, especially in the peripheral nervous system, causing a progressive sensory and motorial polyneuropathy.

Symptoms

Usually manifesting itself between 20 and 40 years of age, it is characterized by pain, paresthesia, muscular weakness and autonomic dysfunction. In its terminal state, the kidneys and the heart are affected. In the absence of a liver transplant, FAP is invariably fatal.

Epidemiology

This disease is endemic in Portuguese locations Póvoa de Varzim and Vila do Conde (Caxinas), with more than 1000 affected people, coming from about 500 families, where 70% of the people develop the illness. It was brought by Vikings from Scandinavia during the Middle Age. In northern Sweden, more specifically Piteå, Skellefteå and Umeå, 1.5% of the population has the mutated gene. There are many other populations in the world who exhibit the illness after having developed it independently.

Bibliography

Andrade C., A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves, Brain 1952; 75:408-27.

External links

Template:SIB

Template:WH Template:WikiDoc Sources